Using Oral Valacyclovir to Treat Patients With Refractory IC/BPS

• Status: Recruiting
• Trial end date: 2022-04-30
• Target enrollment: 0
• Participant gender: All

Summary

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a collective term referring to disorders which is characterized by lower urinary tract symptoms, including bladder pain/discomfort, frequent urination without evidence of bacterial infection. The etiology of IC/BPS is still uncertain, and most current treatment for IC/BPS are only symptoms control. Our previous study revealed Epstein-Barr virus (EBV) infection presented in the IC/BPS bladders and involved the pathogenesis. Hence, using anti-viral medication valacyclovir for the patients with IC/BPS might have clinical efficacy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Buddhist Tzu Chi General Hospital
• Collaborators: Hualien Tzu Chi General Hospital; Ministry of Science and Technology, Taiwan
• Treatments: Valacyclovir

Criteria

Inclusion Criteria:

• patients with IC/BPS

Exclusion Criteria:

• patients with neurogenic bladder

• patients with bladder outlet obstruction

• patients with lymphoma

• patients with bacteria cystitis